Hunt Companies Finance Trust Inc
Change company Symbol lookup
Select an option...
HCFT Hunt Companies Finance Trust Inc
BHV BlackRock Virginia Municipal Bond Trust
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
Go

Financials : Mortgage Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Hunt Companies Finance Trust, Inc., formerly Five Oaks Investment Corp., is a real estate specialty finance company. The Company is focused on investing in a portfolio of mortgage-backed securities (MBS), mortgage loans and other real estate related investments. It is engaged in various real estate businesses, including multifamily ownership, non-bank agency lending, loan servicing, property management, construction, development and military housing. It offers a suite of products, including floating-rate transitional loans, fixed rate commercial real estate loans, mezzanine and preferred financing. It also provides Fannie, Freddie and federal housing administration (FHA) loans for multifamily, student housing, seniors, healthcare and manufactured housing. The Company is externally managed by Hunt Investment Management, LLC.

Closing Price
$2.81
Day's Change
0.02 (0.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.83
Day's Low
2.79
Volume
(Light)
Volume:
13,634

10-day average volume:
20,892
13,634

Johnson & Johnson's stock rallies after Phase 3 trial launched for COVID-19 vaccine candidate

6:56 am ET September 23, 2020 (MarketWatch)
Print

Shares of Johnson & Johnson (JNJ) rallied 2.2% in premarket trading Wednesday, after the health care and pharmaceutical company said it launched its pivotal global Phase 3 trial of its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical subsidiary. J&J said the initiation of the trial comes after its Phase 1/2a study demonstrated that the safety profile and immunogenicity after a single vaccination supported further development. The Phase 3 study is a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of a single vaccine versus placebo, in up to 60,000 adults 18 years old and older, including "significant representation" of people over 60 years old. "With our vaccine candidate now in our global Phase 3 trial, we are one step closer to finding a solution for COVID-19," said Mathai Mammen, global head, Janssen Research & Development. "We used a highly scientific and evidence-based approach to select this vaccine candidate." J&J's stock has slipped 1.1% year to date through Tuesday, while the Dow Jones Industrial Average has lost 4.4%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 23, 2020 06:56 ET (10:56 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.